Clik here to view.
New Funding Allows for the Clinical Development of Novel Cell Based...
London, ON -- (SBWIRE) -- 12/30/2015 -- People with hemophilia have prolonged abnormal bleeding as a result of trauma. Hemophilia A, also called factor VIII (FVIII) deficiency, is the most common form...
View ArticleClik here to view.
Sernova Announces Agreement with CCRM to Produce Specialized Cells for the...
CCRM to establish, optimize and validate methods for producing Sernova’s transformative cell- based therapies for Type-1 diabetesLondon, ON -- (SBWIRE) -- 01/27/2016 -- Sernova Corp., a clinical stage...
View ArticleClik here to view.
Sernova and CTI Clinical Trial Announce Regulatory Collaboration
Sernova provides update on its plans for IND filing with US FDALondon, ON -- (SBWIRE) -- 11/02/2016 -- Sernova Corp., a clinical stage company developing disruptive regenerative medicine technologies...
View ArticleClik here to view.
Sernova Provides Company Outlook on Corporate and Clinical Developments
Sernova reports on active pharma collaboration, upcoming clinical trial and fertile BD pipeline to advance scale of diabetes and hemophilia programsLondon, ON -- (SBWIRE) -- 06/06/2017 -- Sernova...
View ArticleClik here to view.
Sernova Receives US FDA IND Allowance to Initiate a US Clinical Trial of Its...
London, ON -- (SBWIRE) -- 12/14/2017 -- Sernova Corp., a clinical stage company developing regenerative medicine technologies for the long-term treatment of diseases including diabetes and hemophilia,...
View Article
